Lipocine Q3 2026 net loss narrows 79% to $666,192

Bitget2026/11/05 13:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Lipocine’s third-quarter net loss narrowed 79% year over year to $666,192.
Revenue rose to $2.29 million, including $2.1 million in license and collaboration revenue.
Unrestricted cash, cash equivalents and marketable investment securities totaled approximately $28.5 million as of November 4, 2026.
The Phase 3 BLOOM study for postpartum depression began in September, targeting approximately 120 participants to support a potential NDA submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611050800PR_NEWS_USPR_____LA88493) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lipocine Q3 2026 net loss narrows 79% to $666,192

You may also like

Crypto prices